Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature
2016-004091-21Phase 2Unknown
- Sponsor
- University College London
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in castration-resistant prostate cancer (CRPC), sponsored by University College London. Primary endpoint: Composite response rate. Status: unknown.
02
Drugs
nivolumabipilimumab
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2016-004091-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004091-21.